Management of Joint Pain in Non-Hodgkin Lymphoma

The National Comprehensive Cancer Network recommends managing joint pain in Non-Hodgkin Lymphoma patients based on the underlying cause, with tumor flare reactions requiring corticosteroids and antihistamines, while direct lymphomatous joint involvement necessitates systemic chemotherapy targeting the lymphoma itself 1
For patients receiving lenalidomide or other immunomodulatory agents, tumor flare reactions are a specific cause of joint pain that requires immediate recognition and treatment, characterized by painful lymph node enlargement with local inflammation, spleen enlargement, low-grade fever, and/or rash, most common in patients with bulky lymph nodes (>5 cm) 1
The treatment protocol for tumor flare reactions includes corticosteroids, such as prednisone 25-50 mg PO daily for 5-10 days, and antihistamines, such as cetirizine 10 mg PO QID or loratadine 10 mg PO daily, to manage associated symptoms 1
In patients with bulky lymph nodes (>5 cm), consider prophylactic corticosteroids before initiating lenalidomide, with prednisone 20 mg PO daily for 5-7 days, followed by rapid taper over 5-7 days, to prevent tumor flare reactions 1

Diagnostic and Treatment Considerations

Do not mistake tumor flare reactions for disease progression, as these are inflammatory responses to treatment that respond to corticosteroids, not treatment discontinuation, and require prompt recognition and management 1